参考文献/References:
［1］石一复. GTD /GTN诊治进展和争议问题 ［J］. 实用肿瘤杂志, 2016, 31(6):488-490.
［2］Iwase A, Sugita A, Hirokawa W, et al． Anti-Mullerianhormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia ［J］．Eur J Obstet Gynecol Reprod Biol, 2013, 167(2) : 194-198.
［3］于海林, 奚美丽, 鹿欣. 妊娠滋养细胞疾病患者生育相关问题［J］.妇产与遗传（电子版）, 2017, 7(4)：3-6.
［4］Braga A, Maesta I, Michelin OC, et al． Maternal and perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia in Brazilian women［J］．GynecolOncol, 2009, 112(3) : 568-571．
［5］Bedoschi G, Turan V, Oktay K. Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: is it protective?［J］. Curr Breast Cancer Rep, 2013, 5(4) : 302-308．
［6］Del ML, Ceppi M, Poggio F, et al． Gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials ［J］. Cancer Treat Rev, 2014, 40(5) : 675-683．
［7］Mangili G, Lorusso D, Brown J, et al． Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup ［J］．Int J Gynecol Cancer, 2014, 24（9 Suppl3) : S 109-S 116．
［8］Akoury E, Gupta N, Bagga R, et al. Live births in women with recurrent hydatidiform mole and two NLRP7 mutations ［J］. Reprod Biomed Online, 2015, 31(1): 120- 124.
［9］沈曦, 陈秋菊, 匡延平. 妊娠滋养细胞疾病史的不孕患者体外受精/卵胞质内单精子显微注射结局分析 ［J］.中华生殖与避孕杂志, 2018, 38(8):671-676.
［10］Williams D, Hodgetts V, Gupta J. Recurrent hydatidiform moles［J］.Eur J ObstetGynecolReprodBiol, 2010, 150(1):3-7.
［11］石一复主编. 葡萄胎、绒毛膜癌及相关疾病 ［M］. 北京: 人民军医出版社, 2006: 101.
［12］向阳主编. 宋鸿钊滋养细胞肿瘤学 ［M］. 第3版.北京: 人民卫生出版社, 2011: 75.
［13］石一复. 对低危型GTN单一化疗的浅识 ［J］. 中国实用妇科与产科杂志, 2016, 32(8): 769-771.
［14］石一复. 12年来第1～4版FIGO妊娠滋养细胞疾病分期、分类及临床实践指南的演变和思考［J］. 国际妇产科学杂志, 2013, 40(3): 195-197.
［15］Lee YJ, Park JY, Kim DY, et al. Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease ［J］. J GynecolOncol, 2017, 28(2):e 8.
［16］Taylor F, Grew T, Everard J, et al. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid ［J］. Eur JCancer, 2013, 49(15):3184-3190.
相似文献/References:
[1]白莎莎,庞义存,田腊梅,等.Maspin蛋白在葡萄胎恶变中的作用[J].中国计划生育和妇产科,2011,(06):0.
BAI Sha-sha,PANG Yi-cun,TIAN La-mei,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(6):0.
[2]陈彩香*,文锦娣,杨海珍.子宫内膜异位症相关卵巢癌患者临床特点分析[J].中国计划生育和妇产科,2018,(4):62.
CHEN Cai-xiang*,WEN Jin-di,YANG Hai-zhen.Clinical characteristics of patients with endometriosis associated ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(6):62.
[3]袁航,张师前.子宫腺肌病恶变的诊治及注意事项[J].中国计划生育和妇产科,2019,(4):12.
[4]刘红丹,韩旭*.绝经后子宫内膜息肉的恶变风险及诊疗策略[J].中国计划生育和妇产科,2019,(10):40.
[5]周怀君.子宫内膜息肉的药物治疗新进展[J].中国计划生育和妇产科,2021,(7):33.[doi:10.3969/j.issn.1674-4020.2021.07.11]
[J].Chinese Journal of Family Planning & Gynecotokology,2021,(6):33.[doi:10.3969/j.issn.1674-4020.2021.07.11]